抗CD40单克隆抗体研究进展  

Research Advances of Anti-CD40 Monoclonal Antibody——Review

作　　者：罗龙龙[1] 张彦[2] 侯春梅[1] 乔春霞[1] 黎燕[1] 

机构地区：[1]军事医学科学院基础医学研究所,北京100850 [2]中国人民解放军总医院妇产科,北京100853

出　　处：《中国实验血液学杂志》2013年第2期508-512,共5页Journal of Experimental Hematology

基　　金：国家863重大课题(编号2012AA02A302);国家自然科学基金(编号30901381)

摘　　要：CD40及其受体CD40L(CD154)是免疫应答中一对极其重要的共刺激分子,具有广泛的生物学效应。CD40信号激发后通过MAPK(JNK、ERK、p38)途径、PI3K的级联反应及NF-κB和STAT途径等发挥效应。CD40信号与肿瘤免疫密切相关,已成为肿瘤治疗的一个靶分子。目前,已经出现了多株具有良好的肿瘤治疗效果的抗CD40功能抗体,其中CHIR-12.12、SGN-40、CP-870,893等三株抗体发展最快,已先后进入了临床研究。本文对抗CD40抗体的研究进展作一综述,讨论的问题包括CD40的分布,CD40的生理功能,CD40与肿瘤免疫,抗CD40单克隆抗体等。CD40 and its receptor CD40L are a very important pair of co-stimulating molecule in immune response, which have extensive biological effects. After stimulating CD40 signal, it can exert corresponding function through MAPK （JNK, ERK, p38） pathway, PI3K cascade, as well as NF-KB and STAT. The CD40 signal is closely related to tumor immunity, this moleculer has already become targeted-molecule for cancer treatment. Recently, there have been many anti-CD40 monoclonal antibodies displaying good anti-cancer effect, among which CHIR-12.12, SGN-40 and CP- 870,893 developed rapidly and successively have entered clinical research stage. This review focuses the status of anti- CD40 monoclonal antibody, including distribution of CD40, physiological function of CD40, CD40 and tumor immuni- ty, anti-CD40 monoclonal antibodies and so on.

关 键 词：CIMO 单克隆抗体 肿瘤 

分 类 号：R730.51[医药卫生—肿瘤]